返回 Agenda
CT.S3. – The Evolving Clinical Trial Ecosystem in India
Session Chair(s)
Anirban Roy Chowdhury
AVP & Head- Development Center of Excellence Specialty Medicine, Sun Pharma, India
India’s clinical research ecosystem has undergone a remarkable transformation in the last three decades—from a rescue destination for global studies to an innovation-driven hub driving the global drug development through the capability centers of various pharma companies and CROs.
In this session we will discuss opportunities for India to build a resilient future-ready global clinical trial ecosystem, while positioning itself as a strategic hub shaping the future of global drug development through the GCCs.
Speaker(s)
Anirban Roy Chowdhury
AVP & Head- Development Center of Excellence Specialty Medicine, Sun Pharma, India
Introduction by SC: India’s Clinical Research Landscape: A Cycle of Growth, Crisis, and Comeback
Partha Chatterjee
Head, Clinical Trials, CDM & BSP, Syngene, India
Navigating Global Landscape: Multinational Clinical Trials – Challenges and Opportunities
Suneela Milind Thatte
Head R&D India, Merck KGaA, India
GCCs in India: How Leading Pharma Companies Are Harnessing India’s Strategic Talent Potential For Advancing Global Clinical Research
Dr. Phuc (Phillip) Nguyen
Regulator and Policy Advisor U.S. FDA Office, U.S. Embassy , India
With the Additional Participation of: